Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis
NCT00126139 · University of Zurich · PHASE3 · terminated · last registry update 2007-05-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Higher hemorrhage rates of Abciximab in ABESST II trial” | – | Registry record, University of Zurich |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGB3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2008-03-19Phase 3 first posted: University Hospital, Strasbourg, France, Abciximab + Abciximab placebo (NCT00638638)
- 2008-01-10Phase 3 first posted: Catholic University of the Sacred Heart, adenosine + nitroprusside (NCT00590070)
- 2007-12-06Also stopped (terminated): Attenuon, ATN-161 (NCT00131651)
- 2007-05-03Also stopped (terminated): University of Zurich, Abciximab (NCT00167765)
- 2007-01-25Phase 3 first posted: GlaxoSmithKline, Abciximab + Eptifibatide (NCT00426751)
- 2006-05-16Also stopped (terminated): Azienda Sanitaria Ospedaliera, abciximab (NCT00320229)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision